Sqilline Health’s Post

Early cancer detection is crucial for improving cure rates and saving lives, and according to the article on Health Affairs, well-crafted health policies play a vital role in making this a reality. Policies like expanding access to cancer screenings, addressing social determinants of health that hinder access to healthcare, and strengthening primary care, all contribute to a landscape where early detection is more achievable. Public education initiatives that emphasize the importance and curability of early-stage cancers further empower individuals to take charge of their health. By creating and modifying policies with early detection in mind, we can collectively shift the tides against cancer, equipping patients, providers, and healthcare systems with the tools needed to save lives. #earlydetection #cancerawareness #screeningsaveslives https://lnkd.in/gxCmcycN

At CancerIQ, we're embracing the shift toward more proactive health management by making cancer risk assessments accessible directly to patients through familiar digital platforms. This approach not only supports individual health empowerment but also enhances population health by enabling earlier cancer risk detection at scale. By empowering individuals to initiate their own screening processes, we're lowering barriers and improving health outcomes across diverse patient populations. How could integrating patient-initiated screenings add to your health system’s approach to preventive care and population health management? #CancerIQ #CancerPrevention #PopulationHealth #CancerRisk #HealthTech https://lnkd.in/gknk8YHh

Ontada's commitment to support EOM data submission via mCODE standards. The U.S. healthcare systems can really benefit from reduction in administrative burden and accelerated time-to-insight with adoption of industry standards like FHIR/mCODE.

In our latest #340BInformed blog post, we discuss recent research published in Health Affairs highlighting the critical role of #340B in supporting rural hospitals that treat cancer patients. bit.ly/463IXmg   The study underscores how 340B savings contribute to expanding #cancer care services in underserved areas. With more than 46 million Americans living in #rural regions and facing challenges in accessing quality health care, this research sheds light on one promising solution. The findings emphasize the importance of 340B in bridging #healthcare gaps.   That is why we continue the fight to #Protect340B. 

Health as a human right, and #CancerCare as a human priority. On the occasion of #WorldHealthDay and the World Health Organization’s anniversary, this year's theme "My health, my right" underscores the urgency to hasten our response to the increasing frequency of sudden health shifts impacting numerous lives. Data presented in a recent report (https://ow.ly/Mpye50R93Gf) shows that #UniversalHealthCoverage, which aims to ensure quality health services for all individuals regardless of their location, has still a long way to go, especially in #oncology. 📌To learn more about this topic, read Dario Trapani’s article in the #ESMODailyReporter. https://ow.ly/JrFW50R93Ck

What does it take to lead with #empathy in modern healthcare? The #NHS should strive to improve the #health and #wellbeing of people as well as the experiences of health and care. We should do this with compassion, humanity and kindness, respecting people’s values and their right to make choices about their care. Read our article at the National Health Executive which includes the link to the Yes to Life Charter for Oncology. https://lnkd.in/eM9--3yZ

Recent innovation from the NHS through expanding the use of a secure research platform, OpenSAFELY, beyond Covid-19 to explore new treatments for major diseases like cancer, diabetes, and asthma. GPs and researchers will analyse data in GP systems without accessing patient-identifiable info, aiming to uncover life-saving advances. OpenSAFELY, developed with the University of Oxford, has already played a crucial role in over 150 projects during the pandemic. Now, it's set to unlock the power of patient data for broader health breakthroughs. Source article: https://lnkd.in/e5gBJR9X #HealthcareInnovation #Research #NHSUpdates #Healthcare #DigitalHealth #DigitalHealthcare #PatientCare #DigitalPatient #PatientAccess #PatientPathways #Innovation #FutureofHealthcare #NHS

⚡Payers’ coverage policies will impact MCED test adoption and access; thus, their perspectives must be understood. Private payers should be stakeholders of a national MCED policy and equity agenda. What do payers say about MCED tests? This publication examined views, coverage barriers, and evidentiary needs for MCED from 19 private payers collectively covering 150 000 000 enrollees: 🎯 84% saw MCED test’s potential merit for cancers without current screening 🎯 37% saw MCED's merit for cancers with existing screening 🎯 73% stated largest coverage barriers were inclusion of cancers without demonstrated benefits of early diagnosis 🎯 53% considered a high false-negative rate as a barrier 🎯 53% stated lack of care protocols for MCED–detected but unconfirmed cancers as a barrier 🎯 58% would not require mortality evidence and would accept surrogate endpoints 🎯 64% would accept rigorous RWE in the absence of a large RCT 🎯 74% did not expect MCED to reduce disparities due to potential harm from overtreatment Payers’ perspectives and evidentiary needs may inform MCED test developers, researchers producing evidence, and health systems framing MCED screening programs. Private payers should be stakeholders of a national MCED policy and equity agenda. What are your thoughts on the topic? #cancerscreening #mced #healthpolicy #healtheconomics #publichealth #publicpolicy #cancer https://lnkd.in/dP_VV4qy

The study by Professor Stephen Duffy and colleagues shows that low-dose CT lung cancer screening benefits all socioeconomic groups equally. This research, published in Lancet Regional Health Europe, reveals that individuals from lower socioeconomic backgrounds receive the same survival benefits as those from more affluent groups. Additionally, deaths from COPD and emphysema, more common in deprived populations, were reduced with screening. This supports the need for inclusive screening programmes to address health disparities and improve public health. As healthcare providers, we must advocate for targeted screening to ensure equitable access and maximise its life-saving potential. #lungscreen #CT #public

Kristian Helin’s fantastic article in this weekend’s Observer calls out the damage of Brexit and the loss of the EMEA to the UK’s clinical trial standing. We’d also add that the increasing pressures of inadequate time and resource on healthcare providers are impacting their capacity for trial involvement. The government, industry and academia all need to work together to make it easier and simpler for centres, clinicians and people to play their role in the battle against cancer and ensure the UK remains a great place to run effective clinical trials. We believe that digital technology can go a long way to helping us achieve this. You can find out more about uMed’s approach here: https://lnkd.in/eRCMNndX #clinicalresearch #clinicaltrials #patientrecruitment #medicalresearch #healthcare #healthtechnology https://lnkd.in/eN_7QqCP